Zentalis Pharmaceuticals: Hanging On For One Last Shot At PROC Approval [Seeking Alpha]
Zentalis Pharmaceuticals, Inc. - common stock (ZNTL)
Company Research
Source: Seeking Alpha
ZNTL's valuation has plummeted over 85% since late 2023, driven by clinical setbacks, a partial FDA hold, and market skepticism despite a strong cash position into 2027. Denali trial data in Cyclin E1+ patients shows promising response rates versus chemotherapy, but high discontinuation rates and niche market potential temper optimism. While a contrarian opportunity exists if Denali data is positive, the risk of further downside and potential delisting keeps me on the ZNTL sidelines for now. Eoneren/E+ via Getty Images Investment Overview Back in November 2023, I covered Zentalis Pharmaceuticals, Inc. ZNTL ) in a deep dive note for Seeking Alpha - I gave stock a Sell rating, with shares priced at $11.70 - today, they trade at a More on my IG service If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscr
Show less
Read more
Impact Snapshot
Event Time:
ZNTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZNTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZNTL alerts
High impacting Zentalis Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ZNTL
News
- Zentalis Pharmaceuticals (NASDAQ:ZNTL) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ZNTL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall MarketBeat
- Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price target lowered by analysts at Morgan Stanley from $8.00 to $4.00. They now have an "equal weight" rating on the stock.MarketBeat
- Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $4.00 price target on the stock.MarketBeat
- Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its "market perform" rating reaffirmed by analysts at Leerink Partners.MarketBeat
- Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational ProgressGlobeNewswire
ZNTL
Earnings
- 11/10/25 - Beat
ZNTL
Sec Filings
- 11/12/25 - Form SCHEDULE
- 11/10/25 - Form 10-Q
- 11/10/25 - Form 8-K
- ZNTL's page on the SEC website